Inhibition of SARS-CoV-2 3CL Protease by Crotamin Peptide Derivatives in L- and D-Enantiomeric Form

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes peptides derived from crotamine, provided in both L- and D-enantiomeric forms, which can inhibit the 3CL protease enzyme of the SARS-CoV-2 virus. These peptides—and their homologs or fragments—are intended for use in pharmaceutical applications, particularly to treat COVID-19 by blocking a key viral enzyme required for replication.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of antiviral drugs to treat COVID-19
• Design of therapeutic peptides for inhibiting coronavirus replication
• Use in pharmaceutical formulations for acute SARS-CoV-2 infection management
• Creation of peptide-based drug candidates against current or future coronavirus outbreaks
• Use in combination therapy with other antivirals

BenefitsContent extracted from patent full text and abstract with AI.

• Targeted inhibition of the SARS-CoV-2 3CL protease, an essential viral enzyme
• Potential to significantly reduce the replication of the virus in infected patients
• Availability in both L- and D-enantiomeric forms may improve stability, bioavailability, and resistance to enzymatic degradation in the body
• Leads to development of new treatments for COVID-19, potentially improving patient outcomes
• Peptide-based therapeutics may have lower toxicity and higher specificity compared to traditional small-molecule drugs

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Described is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 as well as homologues, fragments and parts thereof, its use for inhibiting SARS-CoV-2 3CL protease, such a peptide for inhibiting SARS-CoV-2 3CL protease and such a peptide for use as a medicament, in particular for use in the treatment of COVID-19.